|
| Press Releases |
|
 |
|
| Friday, June 28, 2024 |
|
|
Eisai: "LEQEMBI" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in China |
| China is the third country to launch LEQEMBI following the United States and Japan. more info >> |
|
| Friday, June 21, 2024 |
|
|
Eisai Continues Contract for FY2024 Dementia Examination Project by Tokyo Bunkyo City |
| Eisai Co., Ltd. announced today that the company has achieved the pre-set performance indicators in FY2023 for the dementia examination project in Bunkyo City, Tokyo, which the company has been commissioned to conduct in order to raise awareness of dementia and promote early detection, and will continue the commission for this project in FY2024. more info >> |
|
| Monday, June 10, 2024 |
|
|
FDA Accepts Eisai's Filing of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease |
| Eisai Co., Ltd. and Biogen Inc. announced today that that the U.S. Food and Drug Administration (FDA) has accepted Eisai's Supplemental Biologics License Application (sBLA) for monthly lecanemab-irmb (U.S. brand name: LEQEMBI) intravenous (IV) maintenance dosing. more info >> |
|
| Monday, June 3, 2024 |
|
|
Eisai Named to List of The Time 100 Most Influential Companies |
| TIME reveals the TIME100 Most Influential Companies list, highlighting companies making an extraordinary impact around the world. more info >> |
|
|
Eisai Strengthens Venture Investment Business Aimed at Accelerating Drug Discovery Innovation and Establishment of Ecosystem Platform |
| Eisai Co., Ltd. announced today that the company decided to strengthen and continue its venture investment business, which launched in 2019, with the aim of discovering innovative technologies and services, supporting venture businesses with such technologies and partnering with those businesses in the future, so as to accelerate drug discovery innovation and the establishment of the ecosystem platform. more info >> |
|
| Tuesday, May 28, 2024 |
|
|
LEQEMBI (lecanemab) Approved for the Treatment of Alzheimer's Disease in South Korea |
| Eisai Co., Ltd. and Biogen Inc. announced today that the Ministry of Food and Drug Safety (MFDS) in South Korea has approved humanized anti-soluble aggregated amyloid-beta (Abeta) monoclonal antibody "LEQEMBI" (lecanemab) for treatment in adult patients with mild cognitive impairment due to Alzheimer's disease (AD) or mild AD (early AD). more info >> |
|
| Thursday, May 23, 2024 |
|
|
Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024 |
| Eisai Co., Ltd. announced today the presentation of research across multiple types of cancer from its oncology portfolio and pipeline during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO24), which is taking place virtually and in-person in Chicago, Illinois from May 31 to June 4. more info >> |
|
| Wednesday, May 22, 2024 |
|
|
Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Launched In Japan |
| Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac group announced today that they have launched the anti-rheumatic agent "Metoject Subcutaneous Injection 7.5mg Pen 0.15mL, 10mg Pen 0.20mL, 12.5mg Pen 0.25mL and 15mg Pen 0.30mL" (methotrexate, "MTX"), in Japan. more info >> |
|
| Wednesday, May 15, 2024 |
|
|
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status |
| LEQEMBI is indicated for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD). more info >> |
|
| Monday, May 13, 2024 |
|
|
Eisai's Antiepileptic Drug Fycompa Approved in China for Adjunctive Treatment of Primary Generalized Tonic-Clonic Seizures |
| Eisai Co., Ltd. announced today that it has received approval in China for the additional indication of its in-house discovered antiepileptic drug (AED) Fycompa (generic name: perampanel hydrate) for adjunctive treatment of primary generalized tonic-clonic seizures in patients with epilepsy aged 12 years and older. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Announcing Zion Shores
Apr 18, 2025 23:06 HKT/SGT
|
|
|
FXSpire Debuts in Dubai as Forex Traders Seek Smarter Tools Amid Global Uncertainty
Apr 18, 2025 21:00 HKT/SGT
|
|
|
FXiBot Launches with a Precision Strategy for GBP/USD Trading
Apr 18, 2025 20:00 HKT/SGT
|
|
|
Fujitsu Kozuchi AI technologies assist AKOS AI in delivering solutions for EU AI compliance
Apr 18, 2025 17:41 JST
|
|
|
Leqembi (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union
Apr 18, 2025 16:52 JST
|
|
|
Hitachi Industrial Equipment Systems Launches Next-Generation Inverter System to Support Stable, Resilient Power Grids
Apr 18, 2025 16:46 JST
|
|
|
Thailand's Brewing Industry Gets a Boost with Life Below Labs' Local Yeast Hub
Apr 18, 2025 13:15 HKT/SGT
|
|
|
A Strategic Event for HR Leaders and Experts to Drive Transformation in the Saudi Workforce
Apr 18, 2025 10:22 HKT/SGT
|
|
|
PerfectSwell(R) Zion To Start Construction
Apr 17, 2025 19:00 HKT/SGT
|
|
|
OMP Positioned Highest for Ability to Execute in the 2025 Gartner(R) Magic Quadrant(TM) for Supply Chain Planning Solutions
Apr 17, 2025 17:00 HKT/SGT
|
|
|
Under the patronage of Maktoum bin Mohammed DIFC to host 3rd edition of Dubai FinTech Summit on 12-13 May 2025
Apr 17, 2025 15:26 HKT/SGT
|
|
|
MHIEC Receives Order from the Bureau of Sewerage of the Tokyo Metropolitan Government for Rebuilding of Sewage Sludge Incineration Facility
Apr 17, 2025 14:44 JST
|
|
|
Fiskl and Airwallex Transform SME Finance with AI 
Apr 17, 2025 12:30 HKT/SGT
|
|
|
Fujitsu collaboration with Supermicro and Nidec to reduce data center energy consumption
Apr 17, 2025 10:32 JST
|
|
|
CBL International Limited Reports 2024 Full-Year Results
Apr 17, 2025 09:17 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
